Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.
Zhu FC, Hou LH, Li JX, Wu SP, Liu P, Zhang GR, Hu YM, Meng FY, Xu JJ, Tang R, Zhang JL, Wang WJ, Duan L, Chu K, Liang Q, Hu JL, Luo L, Zhu T, Wang JZ, Chen W. Zhu FC, et al. Among authors: zhu t. Lancet. 2015 Jun 6;385(9984):2272-9. doi: 10.1016/S0140-6736(15)60553-0. Epub 2015 Mar 25. Lancet. 2015. PMID: 25817373 Clinical Trial.
Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine.
Zhou Y, Li JX, Jin PF, Wang YX, Zhu FC. Zhou Y, et al. Among authors: zhu fc. Expert Rev Vaccines. 2016 Jul;15(7):803-13. doi: 10.1080/14760584.2016.1191357. Epub 2016 Jun 6. Expert Rev Vaccines. 2016. PMID: 27206811 Free article. Review.
Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
Zhu FC, Wurie AH, Hou LH, Liang Q, Li YH, Russell JB, Wu SP, Li JX, Hu YM, Guo Q, Xu WB, Wurie AR, Wang WJ, Zhang Z, Yin WJ, Ghazzawi M, Zhang X, Duan L, Wang JZ, Chen W. Zhu FC, et al. Lancet. 2017 Feb 11;389(10069):621-628. doi: 10.1016/S0140-6736(16)32617-4. Epub 2016 Dec 23. Lancet. 2017. PMID: 28017399 Clinical Trial.
Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
Li JX, Hou LH, Meng FY, Wu SP, Hu YM, Liang Q, Chu K, Zhang Z, Xu JJ, Tang R, Wang WJ, Liu P, Hu JL, Luo L, Jiang R, Zhu FC, Chen W. Li JX, et al. Among authors: zhu fc. Lancet Glob Health. 2017 Mar;5(3):e324-e334. doi: 10.1016/S2214-109X(16)30367-9. Epub 2016 Dec 23. Lancet Glob Health. 2017. PMID: 28017642 Free article. Clinical Trial.
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China.
Wang SY, Liu SZ, Chu K, Zhao Y, Zhu FC, Hu YM, Meng FY, Li JX, Luo L, Yang JY, Liu P, Yu J. Wang SY, et al. Among authors: zhu fc. Expert Rev Vaccines. 2017 Nov;16(11):1155-1169. doi: 10.1080/14760584.2017.1374181. Epub 2017 Sep 18. Expert Rev Vaccines. 2017. PMID: 28870140 Free article. Clinical Trial.
232 results